Safer, rejection-free transplantation is now possible.
Cell Source’s Veto Cell protocols are overcoming allogeneic transplantation’s greatest challenges, including the need to find donors, rejection, Graft vs. Host Disease, and life-threatening infections.
Areas of Therapeutic Focus
Stem Cell Transplantation
(e.g. bone marrow transplantation)Cell Source’s partially-matched allogeneic T-cell Depleted Megadose BMT/HSCT Protocol with anti-viral Veto Cells ensures safe engraftment under reduced-intensity conditioning. No post-procedure immunosuppression needed.
Cancer
Cell Source’s therapeutic approach to leukemia, lymphoma, and myeloma combines the cancer-targeting and killing of a CAR-T cell with the persistence of a Veto Cell in a single T-cell, thus providing sustained protection from cancer relapse.
Organ Transplants
Cell Source’s safe organ transplantation approach utilizes Veto cells’ selective immune targeting to enable the transplant recipient’s immune system to permanently accept organs from partially-matched donors. This eliminates the current requirement for lifelong, daily post-transplant anti-rejection therapy, resulting in significant increases in both quality of life and life expectancy.
Non-Malignant Disease
Type-1 Diabetes. Sickle-cell Anemia. Multiple Sclerosis. Cell Source’s straightforward approach utilizes BMT with Veto Cells to permanently repair the patient’s immune system so that it will stop attacking healthy tissue.
Selective Immune Response
Veto Cells (orange) lure and destroy anti-donor T-cells (green), allowing the patient’s body to accept transplants without the use of aggressive immune suppression.
Scientific Leadership
For over 40 years, Professor Yair Reisner, Ph.D has pioneered significant breakthroughs in immunology. As the Chairman of Cell Source’s Scientific Advisory Board and the Principal Investigator of Cell Source’s sponsored research at MD Anderson Cancer Center, Dr. Reisner is leading the efforts to translate these breakthroughs into commercial therapies.
Development History
